AU2002228316A1 - Carbazole derivatives and their uses as heparanase inhibitors - Google Patents

Carbazole derivatives and their uses as heparanase inhibitors

Info

Publication number
AU2002228316A1
AU2002228316A1 AU2002228316A AU2002228316A AU2002228316A1 AU 2002228316 A1 AU2002228316 A1 AU 2002228316A1 AU 2002228316 A AU2002228316 A AU 2002228316A AU 2002228316 A AU2002228316 A AU 2002228316A AU 2002228316 A1 AU2002228316 A1 AU 2002228316A1
Authority
AU
Australia
Prior art keywords
carbazole derivatives
heparanase inhibitors
heparanase
inhibitors
carbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228316A
Other languages
English (en)
Inventor
Maty Ayal-Hershkovitz
Neta Ilan
Avi Koller
Ofra Levy
Daphna Miron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Strategy and Marketing Ltd
Original Assignee
Insight Strategy and Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy and Marketing Ltd filed Critical Insight Strategy and Marketing Ltd
Publication of AU2002228316A1 publication Critical patent/AU2002228316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2002228316A 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors Abandoned AU2002228316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26430401P 2001-01-29 2001-01-29
US60/264,304 2001-01-29
PCT/IL2002/000079 WO2002060867A2 (fr) 2001-01-29 2002-01-29 Derives de carbazole et leur utilisation en tant qu'inhibiteurs d'heparanase

Publications (1)

Publication Number Publication Date
AU2002228316A1 true AU2002228316A1 (en) 2002-08-12

Family

ID=23005445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228316A Abandoned AU2002228316A1 (en) 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors

Country Status (2)

Country Link
AU (1) AU2002228316A1 (fr)
WO (1) WO2002060867A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
JP2006506379A (ja) 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物
PT1620429E (pt) * 2003-04-11 2009-04-28 Glenmark Pharmaceuticals Sa Novos compostos heterocíclicos úteis para o tratamento de perturbações inflamatórias e alérgicas: processo para a sua preparação e composições farmacêuticas que os contêm
US20080025969A1 (en) * 2004-01-29 2008-01-31 Cell Zome Ag Treatment of Neurodegenerative Diseases by the Use of Gpr49
JP2007525494A (ja) * 2004-02-06 2007-09-06 インサイト バイオファーマシューティカルズ リミテッド ヘパラナーゼ阻害剤及びその使用
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
CA2570884C (fr) * 2004-06-16 2016-04-19 Jack Arbiser Formulations de carbazole destinees au traitement du psoriasis et de l'angiogenese
CA2583497A1 (fr) 2004-10-13 2006-04-20 Glenmark Pharmaceuticals S.A. Procede de preparation de n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
UA88795C2 (ru) 2004-12-17 2009-11-25 Гленмарк Фармасьютікалс С.А. Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений
ES2569881T3 (es) 2005-06-08 2016-05-12 The University Of North Carolina At Chapel Hill Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos
AU2007312880A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2010019271A1 (fr) * 2008-08-15 2010-02-18 Georgetown University Régulateurs fluorescents de l'expression de rassf1a et de la prolifération de cellules cancéreuses humaines
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2014031986A1 (fr) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Composés pro-neurogéniques
EP2925129A4 (fr) * 2012-08-24 2016-06-08 Univ Texas Composés pro-neurogènes
US9908863B2 (en) 2013-01-10 2018-03-06 Merck Patent Gmbh Piperidinylcarbazoles
WO2014143985A1 (fr) 2013-03-15 2014-09-18 Pharmatrophix, Inc. Mimétiques de neurotrophine bdnf non peptidiques
AU2014227623B2 (en) 2013-03-15 2018-08-16 Pharmatrophix, Inc. Non-peptide BDNF Neurotrophin mimetics
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
EP3052190A4 (fr) * 2013-10-01 2017-07-19 New York University Composés amino, amido, et hétérocycliques à titre de modulateurs de l'activité rage et leurs utilisations
EP3068388A4 (fr) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Composés neuroprotecteurs et leur utilisation
WO2015070237A1 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Produits chimiques neuroprotecteurs et leurs procédés d'identification et d'utilisation
CN106573918B (zh) 2014-07-04 2020-06-16 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物
US20180110799A1 (en) * 2014-09-02 2018-04-26 The Children's Hospital Of Philadelphia Compositions and Methods for the Inhibition of Chondrogenesis
MA41587A (fr) 2014-12-17 2021-04-28 Pimco 2664 Ltd N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique
KR101652305B1 (ko) * 2015-02-02 2016-08-30 충남대학교산학협력단 카바졸 유레아 유도체를 함유하는 혈관 질환의 예방 또는 치료용 조성물
DK3307323T3 (da) 2015-06-15 2022-08-15 Raziel Therapeutics Ltd Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf
US11053255B2 (en) 2015-06-22 2021-07-06 Georgetown University Synthesis of mahanine and related compounds
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
RU2019121873A (ru) * 2016-12-13 2021-01-15 БЕТА ТЕРАПЬЮТИКС ПиТиУай ЛТД Ингибиторы гепараназы и их применение
EP3381906A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composes utiles comme inhibiteurs d'heparanase
CN111217741B (zh) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 氟取代单咔唑类衍生物、其制备方法及应用
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents
FR2696465B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
WO2002060867A2 (fr) 2002-08-08
WO2002060867A3 (fr) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002228316A1 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2002363005A1 (en) Derivatives of uk-2a
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
AU2003249442A1 (en) Kinase inhibitors
AU2003222055A1 (en) Kinase inhibitors
AU2003271566A1 (en) Pyrrolopyrazines as kinase inhibitors
AU2003202263A1 (en) Roh-kinase inhibitors
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2002230057A1 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase